‘Pegfilgrastim, We Are Definitely Going To Take It To The US Market,’ Says Aurobindo

Aurobindo Currently Has Eight Biosimilars In Its Pipeline

 
• By Urtė Fultinavičiūtė

While outlining key dates for its biosimilars portfolio, Aurobindo remains confident in the US market stability for its products.

Man standing at the start of the road, concept of business project milestones
• Source: Shutterstock

More from Biosimilars

More from Products